Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes.

IF 3.4 3区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Metabolites Pub Date : 2025-04-09 DOI:10.3390/metabo15040255

Md Altaf-Ul-Amin, Ahmad Kamal Nasution, Rumman Mahfujul Islam, Pei Gao, Naoaki Ono, Shigehiko Kanaya

{"title":"Drug Repurposing for Non-Alcoholic Fatty Liver Disease by Analyzing Networks Among Drugs, Diseases, and Genes.","authors":"Md Altaf-Ul-Amin, Ahmad Kamal Nasution, Rumman Mahfujul Islam, Pei Gao, Naoaki Ono, Shigehiko Kanaya","doi":"10.3390/metabo15040255","DOIUrl":null,"url":null,"abstract":"Background/objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed drugs for NAFLD by leveraging disease-disease relationships and drug-target data from the BioSNAP database.Methods: A bipartite network was constructed between drugs and their target genes, followed by the application of the BiClusO bi-clustering algorithm to identify high-density clusters. Clusters with significant associations with NAFLD risk genes were considered to predict potential drug candidates. Another set of candidates was determined based on disease similarity.Results: A novel ranking methodology was developed to evaluate and prioritize these candidates, supported by a comprehensive literature review of their effectiveness in NAFLD treatment.Conclusions: This research demonstrates the potential of drug repurposing to accelerate the development of therapies for NAFLD, offering valuable insights into novel treatment strategies for complex diseases.","PeriodicalId":18496,"journal":{"name":"Metabolites","volume":"15 4","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12029302/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolites","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/metabo15040255","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Drug development for complex diseases such as NAFLD is often lengthy and expensive. Drug repurposing, the process of finding new therapeutic uses for existing drugs, presents a promising alternative to traditional approaches. This study aims to identify potential repurposed drugs for NAFLD by leveraging disease-disease relationships and drug-target data from the BioSNAP database.

Methods: A bipartite network was constructed between drugs and their target genes, followed by the application of the BiClusO bi-clustering algorithm to identify high-density clusters. Clusters with significant associations with NAFLD risk genes were considered to predict potential drug candidates. Another set of candidates was determined based on disease similarity.

Results: A novel ranking methodology was developed to evaluate and prioritize these candidates, supported by a comprehensive literature review of their effectiveness in NAFLD treatment.

Conclusions: This research demonstrates the potential of drug repurposing to accelerate the development of therapies for NAFLD, offering valuable insights into novel treatment strategies for complex diseases.

查看原文本刊更多论文

通过分析药物、疾病和基因之间的网络，对非酒精性脂肪性肝病的药物再利用。

背景/目的：复杂疾病如NAFLD的药物开发通常是漫长而昂贵的。药物再利用是为现有药物寻找新的治疗用途的过程，是传统方法的一个有希望的替代方法。本研究旨在通过利用来自BioSNAP数据库的疾病-疾病关系和药物靶标数据，确定潜在的NAFLD再用途药物。方法：构建药物与靶基因之间的二部网络，应用BiClusO双聚类算法对高密度聚类进行识别。与NAFLD风险基因显著相关的聚类被认为可以预测潜在的候选药物。另一组候选者是根据疾病相似度确定的。结果：我们开发了一种新的排名方法来评估和优先考虑这些候选药物，并对其在NAFLD治疗中的有效性进行了全面的文献回顾。结论：本研究证明了药物再利用加速NAFLD治疗发展的潜力，为复杂疾病的新治疗策略提供了有价值的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Metabolites Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

5.70

自引率

7.30%

发文量

1070

审稿时长

17.17 days

期刊介绍： Metabolites (ISSN 2218-1989) is an international, peer-reviewed open access journal of metabolism and metabolomics. Metabolites publishes original research articles and review articles in all molecular aspects of metabolism relevant to the fields of metabolomics, metabolic biochemistry, computational and systems biology, biotechnology and medicine, with a particular focus on the biological roles of metabolites and small molecule biomarkers. Metabolites encourages scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on article length. Sufficient experimental details must be provided to enable the results to be accurately reproduced. Electronic material representing additional figures, materials and methods explanation, or supporting results and evidence can be submitted with the main manuscript as supplementary material.